<DOC>
	<DOCNO>NCT01169597</DOCNO>
	<brief_summary>Polymyalgia rheumatica ( PMR ) common inflammatory condition affect elderly people involve girdle . The mainstay treatment oral glucocorticoid ( GC ) , recent BSR-BHPR guideline suggest initial prednisone dose comprise 15 20 mg appropriate . However , probably dramatic response PMR GC , randomize controlled trial treatment lack . As result , evidence control study efficacy different initial dos drug tapering . Objective study : test 12.5 mg prednisone/day adequate start dose polymyalgia rheumatica ( PMR ) evaluate clinical predictor drug response . Methods : 60 consecutive PMR patient treat start dose 12,5 mg/day prednisone . Clinical , laboratory , ultrasonographic feature record possible predictor response prednisone . Remission define disappearance least 75 % sign symptom PMR normalization ESR CRP within first month , scenario allow steroid tapering .</brief_summary>
	<brief_title>Short Term Efficacy Starting Dose 12.5 mg Prednisone Polymyalgia Rheumatica Patients</brief_title>
	<detailed_description />
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>patient PMR , diagnose accord criterion Bird et al patient arthritis patient giant cell arteritis patient Parkinson 's disease patient hypothyroidism patient scapulohumeral periarthritis patient fibromyalgia patient unable cooperate</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>polymyalgia rheumatica</keyword>
	<keyword>prednisone</keyword>
	<keyword>clinical examination</keyword>
	<keyword>remission</keyword>
	<keyword>ultrasonography</keyword>
</DOC>